Makers of controversial Alzheimer's drug have until 2030 to prove that it works after mixed clinical trials as critics urge FDA to shorten the timeframe Biogen has until 2030 to prove that their newly approved Alzheimer's drug, Aduhelm, actually works as part of FDA conditional approval The House Committee on Oversight and Reform and the House Committee on Energy and Commerce have launched an investigation into the controversial approval of Aduhelm The drug received approval despite mixed clinical trials results, though it did show it could potentially reduce cognitive decline by 22% Lawmakers are concerned about the drug's steep price tag, that will cost $56,000 per year of treatment